Antiphospholipid antibodies

As per available reports about 175 journals, 150 Conferencces, 28 workshops are presently dedicated exclusively to Antiphospholipid antibodies and about 450368 articles are being published on the current trends in Antiphospholipid antibodies.In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to proteomics are being carried out. Antiphospholipid (APL) antibodies are group of antibodies directed against epitopes on plasma proteins that are uncovered by binding of these proteins to anionic phospholipids on plasma membranes. The most commonly used tests to detect APL include lupus anticoagulant (LAC), anticardiolipin (ACL) antibodies, and anti-β2 -glycoprotein I antibodies.

The Journal of Clinical & Cellular Immunology is an academic journal – hosted by OMICS International – a pioneer in open access publishing–and is listed among the top 10 journals in Antiphospholipid Antibodies. Each year research scientists have noticed a rise in the number of congresses being held in this field. The Journal of Clinical & Cellular Immunology provides a unique platform to researchers and scientist to explore the advanced and latest research developments in the field of Antiphospholipid Antibodies, thus bridging the gap between researchers and young scientists.

OMICS Group, the world pioneer for organizing 150 International conferences in USA, Europe, Asia and other continents. Uniquely, 350 peer-reviewed open access journals were operating by OMICS International. This will reflect the scope in current research and development in science, healthcare and technology. With a strong intention to accelerate the scientific discovery, OMICS Group International has been associated with more than150 scientific Societies and Associations.